Market Performance of Roivant Sciences (ROIV) and Peer Comparison
In the most recent 24‑hour trading window that closed at 09:40 AM Central Europe on Friday, 23 September 2026, Roivant Sciences (ticker ROIV) advanced by 1.77 %. The current market price stands at USD 37.45, a modest lift from the previous close. At this level, investors can acquire a share of the company on major exchanges, with the stock’s liquidity supported by a circulating supply of 722.3 million shares.
Key Metrics
| Item | Value |
|---|---|
| Market Capitalisation | USD 26.6 billion |
| 24‑Hour Trading Volume | USD 503.7 million |
| Year‑to‑Date Performance (since last month‑end) | +1.71 % |
| 200‑Day Simple Moving Average | USD 31.07 |
| 52‑Week High | USD 42.50 (08 September 2026) |
| 52‑Week Low | USD 18.27 (27 October 2025) |
The stock’s recent rally sits above its 200‑day moving average, suggesting a positive trend that may appeal to medium‑term investors. However, the price remains considerably below the all‑time high, leaving room for potential upside if the company delivers on its clinical and commercial milestones.
Peer Performance in the Last 24 Hours
| Company | Ticker | % Change | Current Price | Market Cap (USD bn) | P/E Ratio |
|---|---|---|---|---|---|
| MongoDB | MDB | –7.3 % | 362.24 | 31.5 | 542.61 |
| GE Healthcare | GEHC | +3.49 % | 71.42 | 31.2 | 15.87 |
| M & T Bank | MTB | +1.51 % | 222.83 | 31.6 | 11.45 |
| Cheniere Energy | CQP | +0.72 % | 64.22 | 30.9 | 11.60 |
| GE Healthcare (Mexico) | GEHC.MX | –1.11 % | 71.42 | 31.2 | 15.86 |
While most peers are modestly positive, MongoDB’s significant decline underscores sector‑specific volatility. In contrast, GE Healthcare and M & T Bank demonstrate steady, albeit modest, gains. Cheniere Energy’s small uptick reflects its energy‑sector dynamics, and the Mexican listing of GE Healthcare mirrors its U.S. counterpart’s performance.
Company Overview
Roivant Sciences Ltd. is a biotechnology enterprise headquartered in New York, United States, with a global footprint. The firm specializes in the discovery, development, and commercialization of innovative medicines across immunology, oncology, hematology, and dermatology. Its mission centres on transforming healthcare through novel therapeutic approaches. The company is listed on the Nasdaq stock exchange and offers further details on its research portfolio and strategic initiatives at www.roivant.com .
